ZappRx Successfully Advances its Service Organization Control (SOC) 2 Type 2 Report, Validating Secure and Protected Data Exchange

August 10, 2018

SOC 2 Type 2 adaptation demonstrates health tech leader’s commitment to compliance and security of protected patient information


BOSTON--()--ZappRx, Inc., a digital health company that streamlines the prescribing of specialty medications, has completed SOC 2 Type 2 attestation after satisfying the requirements defined by the Association of International Certified Professional Accountants (AICPA). The audit, performed by a major global CPA firm, verifies that ZappRx has built an effective platform that complies with the standards for the security required to process and control digital prescribing and prior authorization for specialty medications.


The SOC 2 Type 2 report provides valuable information for ZappRx to properly assess and address the risks associated with an outsourced service. The report covers five principles against which companies are evaluated. ZappRx was assessed across two of those principles, security and privacy, and achieved compliance with both. The audit examined those specific principles and determined ZappRx satisfied the applicable AICPA criteria.


“We are committed to upholding industry-recognized security and privacy standards to ensure the protection of our customers’ most sensitive information,” said Kyle Kruczek, director of information security at ZappRx. “We apply the most rigid security technology possible in every aspect of our business to ensure patient information remains protected. By achieving SOC 2 Type 2, we have validated for our customers that ZappRx meets the standards set by the AICPA and they can put trust in our solution.”


ZappRx’s commitment to meeting the highest standards in data security, compliance, and risk management is further demonstrated by this latest audit to obtain SOC 2 Type 2. The company conducts regular threat assessments and ongoing system-wide monitoring to ensure the protection of client and patient data.


By achieving SOC 2 Type 2, ZappRx enhances its competitive edge as it continues to expand its services for healthcare providers, biopharma companies, and specialty pharmacies.


About ZappRx

ZappRx streamlines the complex process required to order specialty medications, increasing efficiencies when collecting and maintaining the myriad requisite information for specialty prescribing — including pharmacy information, payer/prior authorization requirements, and relevant clinical history. ZappRx then enables providers, pharmacists, and payers to digitally interact with one another to fill a prescription, reducing the need for faxes and phone calls. The platform is currently live in three disease areas, including Pulmonary Arterial Hypertension (PAH), Idiopathic Pulmonary Fibrosis (IPF), and Cystic Fibrosis, with plans to expand to support prescribing for other areas, including gastroenterology, rheumatology, neurology, and oncology conditions.


Connect with ZappRx on Twitter and LinkedIn.


Matter for ZappRx

Jessica Wolter